The United States FDA has awarded Fast Track Designation to the investigational drug AVB-S6-500 for the potential treatment of platinum-resistant recurrent ovarian cancer. You can find out more detailed information…
In late September, Food and Drug Administration designated "fast track" status to the research and development of CPP-1X/sul for adults diagnosed with Familial Adenomatous Polyposis (FAP). Overseeing the project are Cancer…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
